Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations

Author(s): J. Stitham, J. Hwa

Journal Name: Current Molecular Medicine

Volume 16 , Issue 4 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Prostacyclin (PGI2) and other metabolites of arachidonic acid are increasingly recognized for their role in the pathophysiology of human disease. A growing body of evidence from randomized controlled trials, studies of human prostacyclin receptor (hIP) variants, and IP-receptor knockout studies in mice has shown that PGI2 may have a protective effect on atherothrombotic risk. Increased risk of atherosclerosis and thrombotic sequelae may be attributed, in part, to downregulation of the prostacyclin pathway. Clinical studies with nonsteroidal antiinflammatory drugs (NSAIDs) that were selective for the cyclooxygenase-2 (COX-2) isoenzyme, although protective of mucosa in the gastrointestinal tract, first alluded to a potential role of PGI2 in atherothrombotic risk. Outcomes from early clinical trials showed a 2- to 3-fold increase in risk of incurring a thrombotic event (e.g., myocardial infarction or stroke). Further analyses suggested that atherothrombotic risk is a continuous variable with relative NSAID COX-2 selectivity, and that the COX-2 metabolic product, PGI2, appears to play a key role. Effects of reduced PGI2 levels may be felt in particular by patients with diabetes mellitus, a patient population at the high end of the cardiovascular risk spectrum. Therapies that spare PGI2 may provide the greatest level of protection. The mechanism of protection by PGI2 is under intense investigation.

Keywords: Aspirin, atherothrombosis, diabetes mellitus, prostacyclin, prostacyclin receptor, thromboxane.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [328 - 342]
Pages: 15
DOI: 10.2174/1566524016666160316150728
Price: $65

Article Metrics

PDF: 50
PRC: 1